Editorial: Novel and emerging therapies for the treatment of obesity and related disorders

• Isabel R. Amado,
• Marina Romaní-Pérez,
• Pablo Fuciños,
• Manuel Gil-Lozano,
• Manuel Gil-Lozano,
• Manuel Gil-Lozano

Affiliations

Isabel R. Amado

International Iberian Nanotechnology Laboratory (INL), Braga, Portugal

Marina Romaní-Pérez

Microbiome, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology, Severo Ochoa Centre of Excellence, National Research Council (IATA-CSIC), Valencia, Spain

Pablo Fuciños

International Iberian Nanotechnology Laboratory (INL), Braga, Portugal

Manuel Gil-Lozano

Institute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany

Manuel Gil-Lozano

Joint Heidelberg-Institute for Diabetes and Cancer (IDC) Translational Diabetes Program, Inner Medicine, Heidelberg University Hospital, Heidelberg, Germany

Manuel Gil-Lozano

German Center for Diabetes Research (DZD), Neuherberg, Germany